title: E-cadherin promoter polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients.
abstract: BACKGROUND
  -160C-->A and -347G-->GA polymorphisms in the promoter region decrease E-cadherin gene transcription. Decreased E-cadherin expression predicts poor outcome among patients with cancer. We sought to investigate whether -160C-->A and/or -347G-->GA polymorphisms were associated with the aggressiveness of prostate cancer.
  
  
  METHODS
  TaqMan single nucleotide polymorphism genotyping assay (Applied Biosystems, Foster City, CA) was used to detect -160C-->A and -347G-->GA polymorphisms in deoxyribonucleic acid from the paraffin-embedded prostate tissues of 98 Caucasian patients.
  
  
  RESULTS
  The genotype frequencies were -160C/C: 48% (47 of 98); -160C/A: 44% (43 of 98); -160A/A: 8% (8 of 98); -347G/G: 68% (67 of 98); -347G/GA: 28% (27 of 98); and -347GA/GA: 4% (4 of 98). Using the chi-square test, we found that the polymorphisms -160C-->A and -347G-->GA were not related to other clinical and pathologic parameters (i.e., age, prostate-specific antigen level, Gleason grade, and clinical stage) (P > 0.05). In combination analysis, there was no significant relationship between patients with both -160C/C and -347G/G, and these same parameters (P > 0.05). Using the log-rank test, we found no significant difference in relapse-free survival and overall survival between patients with -160C/C and those with -160A/C or -160A/A (P = 0.0764 and 0.2746, respectively), and also no significant difference between patients with -347G/G and those with -347GA/G or -347GA/GA (P = 0.9416 and 0.7367, respectively). There was also no significant difference in relapse-free survival and overall survival between patients with homozygosities of -160C/-347G and patients with other genotypes (P = 0.1418 and 0.2434, respectively).
  
  
  CONCLUSIONS
  We conclude that E-cadherin -160C-->A and/or -347G-->GA polymorphisms are not associated with the aggressiveness of prostate cancer in Caucasian patients.
authors.affiliation: Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
authors.forename: He-Cheng
authors.initials: HC
authors.lastname: Li
authors.forename: Jeffrey M
authors.initials: JM
authors.lastname: Albert
authors.forename: Eric T
authors.initials: ET
authors.lastname: Shinohara
authors.forename: Qiuyin
authors.initials: Q
authors.lastname: Cai
authors.forename: Andrea
authors.initials: A
authors.lastname: Freyer
authors.forename: Hui
authors.initials: H
authors.lastname: Cai
authors.forename: Carolyn
authors.initials: C
authors.lastname: Cao
authors.forename: Zuofei
authors.initials: Z
authors.lastname: Wang
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Kataoka
authors.forename: Ming
authors.initials: M
authors.lastname: Teng
authors.forename: Wei
authors.initials: W
authors.lastname: Zheng
authors.forename: Bo
authors.initials: B
authors.lastname: Lu
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015820:Cadherins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D016019:Survival Analysis; D044465:White People / Q000235:genetics*
chemical_list: D015820:Cadherins